AAPL327.74+1.15 (+0.35%) ▲|ABBV256.05+2.67 (+1.05%) ▲|ABT99.68-1.98 (-1.95%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.81+4.09 (+3.18%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.15+28.25 (+2.46%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|AAPL327.74+1.15 (+0.35%) ▲|ABBV256.05+2.67 (+1.05%) ▲|ABT99.68-1.98 (-1.95%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.81+4.09 (+3.18%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.15+28.25 (+2.46%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|
27.4 C
New York
Tuesday, July 21, 2026

Tag: kidney disease

newssourceFORcompanyinformationcontent1releasesmarket

Clover Health Set to Join Russell 3000® Index

WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

Novartis completes acquisition of Regulus Therapeutics

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be...

Applied Therapeutics Announces Key Leadership Appointments

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs.

FibroGen Announces 1-for-25 Reverse Stock Split

SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen’s common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company’s existing trading symbol “FGEN,” with the new CUSIP number 31572Q881.

Calliditas Therapeutics Presented at the 62nd European Renal Association Congress

STOCKHOLM, June 9, 2025 /PRNewswire/ -- Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data was presented at the 62nd European...

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsKidney disease

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers